Compare Quest Diagnostics Inc (DGX) vs J B Hunt Transport Services Inc (JBHT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs J B Hunt Transport Services Inc — how do they compare? Quest Diagnostics Inc trades at $204.9 (market cap $22.80B), while J B Hunt Transport Services Inc trades at $276.92 (market cap $26.49B). The key difference: J B Hunt Transport Services Inc is the larger of the two by market cap, and Quest Diagnostics Inc pays the higher dividend (1.67%). Which is the better fit depends on your goals.
| DGX | JBHT | |
|---|---|---|
Market Cap | $22.80B | $26.49B |
Sector | Health | Industrials |
52-Week High | $216.02 | $290.07 |
52-Week Low | $166.42 | $130.65 |
Enterprise Value | $28.82B | $27.78B |
Dividend Yield | 1.67% | 0.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
JB Hunt Transport Services (JBHT) trades at $283.00, up 1.09% with a bullish technical signal from moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 results expected soon. Valuation metrics show a P/E of 43.95 and P/S of 2.25, while profitability remains solid with 5.13% net margin and 16.68% ROE. Analyst consensus is strongly positive with 26 buy ratings and a $280.59 price target.
JBHT demonstrates consistent operational performance with stable cash flow generation, though revenue has declined from 2022 peaks. The stock faces valuation concerns with elevated P/E ratios, while freight market cyclicality presents ongoing business risks. Earnings momentum and strong analyst support provide upside potential, but investors should monitor Q2 earnings results for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About J B Hunt Transport Services Inc
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).
Read more on JBHT →
